Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00327587 · ClinicalTrials.gov registry record · Phase 3
8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,279
- Enrollment target
NCT00327587 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 2,279 participants.
The verdict
NCT00327587, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,279 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of the various combinations of valsartan, HCTZ, and amlodipine in patients with moderate to severe hypertension.
Interventions
- DRUG Valsartan + HCTZ
- DRUG Valsartan + amlodipine
- DRUG Amlodipine + HCTZ
- DRUG Valsartan + amlodipine + HCTZ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,279 participants |
| Start Date | 2006-05 |
| Est. Completion | 2007-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00327587
The ClinicalTrials.gov registry entry for NCT00327587 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,279 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Valsartan + HCTZ is the first listed.
NCT00327587 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00327587 about?
NCT00327587 is a clinical study titled "8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension". The purpose of this study is to determine the safety and efficacy of the various combinations of valsartan, HCTZ, and amlodipine in patients with moderate to severe hypertension.
What is the current status of trial NCT00327587?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,279 participants. The study started on 2006-05. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00327587?
The interventions under investigation include: Valsartan + HCTZ (DRUG), Valsartan + amlodipine (DRUG), Amlodipine + HCTZ (DRUG), Valsartan + amlodipine + HCTZ (DRUG).
Who is sponsoring clinical trial NCT00327587?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.